The strong beat and raised guidance, combined with accelerating operating margin expansion and robust free cash flow, signal durable compounding growth. The stock should re-rate higher. Monitor the August 13 Investor Day for further strategic updates on IDEXX inVue Dx and Cancer Dx platform expansion.
Price Chart
Executive Summary
IDEXX reported Q2 2026 EPS of $4.27, an 8.5% beat vs consensus of $3.93, on revenue of $1.217B (in line with $1.20B consensus). Revenue grew 10% YoY as reported and 9% organic, driven by 11% CAG Diagnostics recurring revenue growth. The company narrowed 2026 revenue guidance to $4.700B-$4.745B (up $5M at midpoint) and raised EPS guidance to $14.69-$14.94 (+$0.14 at midpoint). Operating margin expanded 140 bps to 35.0%. The beat was driven by strong volume growth in VetLab consumables (+15%) and reference lab services (+11%), with the IDEXX inVue Dx installed base surpassing 9,000 instruments. Guidance was raised modestly despite a $15M FX headwind, reflecting confidence in underlying demand trends.
Key Financial Metrics
Key Facts
- Q2 2026 EPS $4.27 beat consensus $3.93 by 8.5%
- Revenue $1.217B, +10% YoY as reported, +9% organic
- CAG Diagnostics recurring revenue +11% reported, +10% organic
- Operating margin 35.0%, +140 bps YoY
- 2026 EPS guidance raised to $14.69-$14.94 from $14.45-$14.90
- 2026 revenue guidance narrowed to $4.700B-$4.745B, +$5M at midpoint
- IDEXX inVue Dx installed base surpassed 9,000 instruments with 1,600+ placements in Q2
- Free cash flow $322.5M in Q2, up 113% YoY
- Gross margin 64.0%, +140 bps YoY
Financial Impact
EPS beat of $0.34 (8.5%) on consensus of $3.93; revenue beat of ~$17M (1.4%) on consensus of $1.20B; guidance raised by $0.14 at midpoint
Risk Factors
- $15M FX headwind in 2026 guidance from a stronger USD
- CAG Diagnostics capital instrument revenue declined 19% YoY as prior-year inVue Dx launch comps normalize
- Rapid assay product revenue growth remains flat (+1%) as testing shifts to Catalyst platform
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-090033 |
| Document: tm2622041d1_8k.htm | 0001104659-26-090033 |
| Document: 0001104659-26-090033-index-headers.html | 0001104659-26-090033 |
| Document: 0001104659-26-090033-index.html | 0001104659-26-090033 |
| Document: 0001104659-26-090033.txt | 0001104659-26-090033 |
| 8-K Data (Synthetic) | 0001104659-26-090033 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $588.09 $545.16 | ▼ −7.30% | ▼ −6.06% | $518.39 (−11.85%) |
May 5, 2026 21w ago | 8-K | $560.55 $550.82 | ▼ −1.74% | ▼ −6.69% | $518.39 (−7.52%) |
Mar 27, 2026 27w ago | DEFA14A | $556.91 $568.05 | ▲ +2.00% | ▼ −10.60% | $518.39 (−6.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access